1/ Q2 sales increased by 49.9% (-56.8% in Q1, -22.7% in H1). H1 operating income amounted to DKK36m (vs DKK65m in H1 14). 2/ Rolling submission of BLA for daratumumab in double refractory multiple myeloma triggered a $15m payment in July.
09 Sep 2015
Decreasing Arzerra
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decreasing Arzerra
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
09 Sep 2015 -
Author:
Armelle Moulin -
Pages:
2
1/ Q2 sales increased by 49.9% (-56.8% in Q1, -22.7% in H1). H1 operating income amounted to DKK36m (vs DKK65m in H1 14). 2/ Rolling submission of BLA for daratumumab in double refractory multiple myeloma triggered a $15m payment in July.